Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance by Sahajpal, panelNikhil S. et al.
eCommons@AKU 
Pathology, East Africa Medical College, East Africa 
7-2021 
Clinical Validation of a Sensitive Test for Saliva Collected in 
Healthcare and Community Settings with Pooling Utility for Severe 
Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance 
panelNikhil S. Sahajpal 




See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_pathol 
 Part of the Pathology Commons 
Authors 
panelNikhil S. Sahajpal, Ashis K. Mondal, Sudha Ananth, Allan Njau, Pankaj Ahluwalia, Vamsi Kota, Kevin 
Caspary, Ted M. Ross, Michael Farrell, and Michael P. Shannon 
Clinical Validation of a Sensitive Test for Saliva
Collected in Healthcare and Community Settings
with Pooling Utility for Severe Acute Respiratory Syndrome
Coronavirus 2 Mass Surveillance
Nikhil S. Sahajpal,* Ashis K. Mondal,* Sudha Ananth,* Allan Njau,y Pankaj Ahluwalia,* Vamsi Kota,z Kevin Caspary,x
Ted M. Ross,{ Michael Farrell,k Michael P. Shannon,** Sadanand Fulzele,yy Alka Chaubey,* Madhuri Hegde,zz Amyn M. Rojiani,*
and Ravindra Kolhe*
From the Departments of Pathology* and Medicinez and the Center for Healthy Aging,yy Medical College of Georgia, Augusta University, Augusta, Georgia;
the Department of Pathology,y Aga Khan University Hospital, Nairobi, Kenya; the 4th Weapons of Mass Destruction Civil Support Team,x Georgia Army
National Guard, Marietta, Georgia; the Center for Vaccines and Immunology,{ University of Georgia, Athens, Georgia; the Institute for Internet Security and
Privacyk and the Advanced Warfighting Technologies Division,** Georgia Tech Research Institute, Georgia Institute of Technology, Atlanta, Georgia; and the




Ravindra Kolhe, M.D., Ph.D.,
Medical College of Georgia,
Augusta University, BAE 2576,
1120 15th St., Augusta, GA
30912. E-mail: rkolhe@
augusta.edu.
The clinical performance of saliva compared with nasopharyngeal swabs (NPSs) has shown conflicting
results in healthcare and community settings. In the present study, a total of 429 matched NPS and
saliva sample pairs, collected in either healthcare or community setting, were evaluated. Phase-1
(protocol U) tested 240 matched NPS and saliva sample pairs; phase 2 (SalivaAll protocol) tested 189
matched NPS and saliva sample pairs, with an additional sample homogenization step before RNA
extraction. A total of 85 saliva samples were evaluated with both protocols. In phase-1, 28.3% (68/
240) samples tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from
saliva, NPS, or both. The detection rate from saliva was lower compared with that from NPS samples
(50.0% versus 89.7%). In phase-2, 50.2% (95/189) samples tested positive for SARS-CoV-2 from saliva,
NPS, or both. The detection rate from saliva was higher compared with that from NPS samples (97.8%
versus 78.9%). Of the 85 saliva samples evaluated with both protocols, the detection rate was 100% for
samples tested with SalivaAll, and 36.7% with protocol U. The limit of detection with SalivaAll protocol
was 20 to 60 copies/mL. The pooled testing approach demonstrated a 95% positive and 100% negative
percentage agreement. This protocol for saliva samples results in higher sensitivity compared with NPS
samples and breaks the barrier to using pooled saliva for SARS-CoV-2 testing. (J Mol Diagn 2021, 23:
788e795; https://doi.org/10.1016/j.jmoldx.2021.04.005)
The outbreak of coronavirus disease 2019 [COVID-19;
caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)] is an ongoing pandemic that has caused
substantial social, economic, and public health strain.
Since its identification in the region of Wuhan, China,
105,962,538 confirmed cases with >2,313,136 COVID-
19erelated deaths have been reported globally (https://
coronavirus.jhu.edu/map.html, last accessed February 7,
2021). Testing, coupled with measures such as social
distancing, masking, maintaining personal hygiene, contact
tracing, quarantine, travel restrictions, and lockdowns, have
hitherto been the most widely adopted strategies to contain
this pandemic.1 Regional policies have been primarily
Disclosures: R.K. has received honoraria, travel funding, and research
support from Illumina, Asuragen, Qiagen, and BMS. M.H. holds stock
options at PerkinElmer Inc. This project has been funded by the National
Institute of Allergy and Infectious Diseases, a component of the National
Institutes of Health, Department of Health and Human Services
(75N93019C00052).
Copyright ª 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0).
https://doi.org/10.1016/j.jmoldx.2021.04.005
jmdjournal.org
The Journal of Molecular Diagnostics, Vol. 23, No. 7, July 2021
dictated by the positivity rate in the respective region(s).
Thus, rapid and accurate detection of SARS-CoV-2 is the
foremost and likely most essential component in controlling
this outbreak and has immediate clinical, epidemiologic, and
policy implications. Various clinical specimens such as
bronchoalveolar lavage, sputum, saliva, nasopharyngeal
swabs (NPSs), oropharyngeal swabs (OPSs), feces, and blood
have been evaluated for detection of SARS-CoV-2 virus.2
NPS and OPS samples are the current standard upper respi-
ratory tract specimens recommended for COVID-19 diag-
nostic testing. However, the collection of NPS samples poses
challenges such as exposure risk to healthcare workers, sup-
ply chain constraints pertaining to swabs and personal pro-
tective equipment, and difficulties with self-collection.
Inappropriate sampling may lead to false-negative results.3e5
Amidst the several other sample types under investigation for
COVID-19 testing, saliva samples are of significant interest
owing to their ease of collection, and ability to alleviate some
of the challenges associated with NPS sampling. True saliva
is defined as the naturally collecting clear liquid that accu-
mulates in the mouth. However, saliva from patients can be
confounded with the presence of mucus or blood, thereby
rendering it difficult to process in the laboratory. Several re-
ports evaluating the clinical performance of saliva compared
with NPS/OPS samples have demonstrated conflicting re-
sults. In a healthcare setting, studies have demonstrated
comparable6e9 and even higher sensitivity of saliva10/early
morning saliva collection11 compared with NPS samples, as
well as reported higher viral titer values in saliva.9
Conversely, deep-throat saliva12 and typical saliva samples
have also been demonstrated to be less sensitive compared
with NPS samples in both healthcare13 and community set-
tings.14 Furthermore, saliva samples are difficult to pipet by
the testing personnel, which leads to increased processing
time.15
Although different collection devices, media, sample
handling, extraction procedure, and real time PCR methods
may have accounted for these discrepancies, a critical facet
of the saliva samples was investigated that, if accounted for,
renders the saliva samples more sensitive than NPS sam-
ples. In this analysis, the saliva samples initially demon-
strated a lower sensitivity compared with NPS samples.
When a simple processing step using the bead mill
homogenizer was introduced, the saliva samples showed
higher sensitivity compared with NPS samples. Not only
did the saliva processing become significantly easier after
using the homogenizer, but the saliva samples could also be
validated with a five-sample pooling strategy. The
Figure 1 Schematic overview of sample processing and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay workflow, depicting
main steps. Matched nasopharyngeal swab (NPS) and saliva sample pairs collected in healthcare and community setting were tested and validated as
follows. Top row: NPS or saliva samples were processed with protocol U for nucleic acid extraction using a semi-automated instrument, followed by real time
PCR for N and ORF1ab gene targets and internal control (IC) used as extraction and real time PCR IC. Middle row: Saliva samples were processed with
SalivaAll protocol that included a saliva homogenization step using a bead mill homogenizer before RNA extraction and downstream processing. Bottom
row: Saliva samples were homogenized using a bead mill homogenizer (SalivaAll protocol) before pooling samples with a five-sample pooling strategy for
SARS-CoV-2 testing.
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SalivaAll protocol is sensitive and detects up to 20 copies/
mL, facilitating utility in saliva sample pooled testing,
which is critical in SARS-CoV-2 mass surveillance. This
single-site study identified both increased and decreased
sensitivity of saliva as a diagnostic sample type, consistent
with the discrepancies reported in the literature, that were
largely believed to be the result of processing challenges.
We contend that with appropriate management of these
processing challenges, saliva samples are more sensitive
compared with the NPS samples.
Materials and Methods
Study Site and Ethics
This single-center diagnostic study was conducted at the
Augusta University (Augusta, GA). This site is a Clinical
Laboratory Improvement Amendmentseaccredited
laboratory for high-complexity testing and is one of the
main SARS-CoV-2 testing centers in the state of Georgia.
Patient Specimens and Setting
The study evaluated 429 matched NPS and saliva samples
(sample pairs) collected from 344 individuals in either a
healthcare or a community setting. Of the 344 individuals,
95 matched clinical specimen pairs were collected in
healthcare setting from individuals at either a medical
nursing home or Augusta University Medical Center, both
in Georgia. In the community setting, 249 matched clinical
specimen pairs were collected from drive-through collection
centers in different regions of Georgia that include Augusta,
Albany, and Atlanta. As a standard protocol in both settings,
NPSs from individuals were collected by a healthcare
worker using a sterile flocked swab placed in a sterile tube
containing 3 mL of viral transport medium (Specimen
Collection and Transport System BD Sterile, catalog
Figure 2 A: Boxplots of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Ct value of both N and ORF1ab genes of all the positive specimens in
phase 1 study. The Ct value of both genes was lower in the nasopharyngeal swab (NPS) than saliva samples. Also included Ct values of internal control (IC) of
all the samples in both specimens. B: Bar graph depicting detection rate with NPS and saliva samples in phase 1 study. C: Boxplots of SARS-CoV-2 Ct value of
both N and ORF1ab genes of all the positive specimens in phase 2 study. The Ct value of both genes was lower in the saliva than NPS samples. Also included Ct
values of IC of all the samples in both specimens. D: Bar graph depicting detection rate with NPS and saliva samples in phase 2 study. Data are given as
means  SD (A and C). *P < 0.05, ***P < 0.001. Saliva-U, unprocessed saliva samples.
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number 220531; Becton Dickinson, Franklin Lakes, NJ).
Before collecting the NPS samples, the individuals were
instructed to provide saliva samples by spitting into a sterile
container (DNA/RNA Shield Saliva Sputum Collection Kit
e DX, catalog number R1210-E; Zymo Research, Irvine,
CA) over which the healthcare worker added 2 mL of viral
transport medium. All samples were stored at 4C temper-
ature and transported to the SARS-CoV-2 testing facility at
Augusta University within 24 hours of sample collection for
further processing.
Assay for the Detection of SARS-CoV-2
The assay is based on nucleic acid extraction followed by
TaqMan-based real time PCR assay to conduct in vitro
transcription of SARS-CoV-2 RNA, DNA amplification,
and fluorescence detection [Food and Drug Administration
(FDA) Emergency Use Authorization assay by Perki-
nElmer Inc., Waltham, MA]. The assay targets specific
genomic regions of SARS-CoV-2: nucleocapsid (N ) gene
and ORF1ab. The TaqMan probes for the two amplicons
are labeled with FAM and ROX fluorescent dyes,
respectively, to generate target-specific signals. The assay
includes an RNA internal control (IC; bacteriophage MS2)
to monitor the processes from nucleic acid extraction to
fluorescence detection. The IC probe is labeled with VIC
fluorescent dye to differentiate its fluorescent signal from
SARS-CoV-2 targets. The samples were resulted as posi-
tive or negative based on the cycle threshold (Ct) values
specified by the manufacturer (Supplemental Table S1).
Phase 1 Study and Sample Processing (Protocol U)
In phase 1 of this study, 240 matched NPS and saliva
sample pairs were tested prospectively for SARS-CoV-2
RNA by real time PCR. Of the 240 samples, 95 were
collected in a healthcare setting and 145 were collected in a
community setting. In brief, all samples were vortexed, and
an aliquot of 300 mL from each sample (NPS or saliva),
positive and negative controls, was added to respective
wells in a 96-well plate. To each well, 5 mL IC, 4 mL
poly(A) RNA, 10 mL proteinase K, and 300 mL lysis buffer
1 were added. The plate was placed on a semi-automated
instrument (Chemagic 360 Instrument; PerkinElmer Inc.)
following the manufacturer’s protocol. The nucleic acid was
extracted in a 96-well plate, with an elution volume of 60
mL. From the extraction plate, 10 mL of extracted nucleic
acid and 5 mL of PCR master mix were added to the
respective wells in a 96-well PCR plate. The PCR method
was set up as per the manufacturer’s protocol on
Quantstudio 3 or 5 (Thermo Fisher Scientific, Waltham,
MA). The samples were classified as positive or negative,
depending on the Ct values specified by the manufacturer
(Figure 1).
Phase 2 Study and Sample Processing (SalivaAll)
In phase 2 of this study, 189 matched NPS and saliva
sample pairs were tested for SARS-CoV-2. Of the 189
samples, 40 were collected in healthcare and 149 were
collected in a community setting. More importantly, 85
samples previously evaluated with protocol U were re-
evaluated with SalivaAll protocol to determine the effect of
bead homogenization. In SalivaAll protocol, an additional
processing step was added for saliva samples that included
aliquoting saliva samples from the collection tubes into
Omni tubes (2 mL reinforced tubes, SKU 19-628D; Omni
International, Kennesaw, GA), which were then placed in
Omni bead mill homogenizer (Bead Ruptor Elite, SKU: 19-
040E; Omni International). The samples were homogenized
at 4.5 m/second for 30 seconds. From the Omni tubes, an
aliquot of 300 mL homogenized saliva samples was added to
96-well plate and downstream processing was performed as
described in protocol U. The NPS sample processing
remained the same as in protocol U (Figure 1). However, an
additional study was done with 189 NPS samples with both
protocol U and SalivaAll protocol to determine if bead
homogenization would affect the clinical sensitivity in NPS
samples.
Studies
The limit of detection (LoD) studies were conducted as per
the FDA guidelines (https://www.fda.gov/medical-devices/
coronavirus-disease-2019-covid-19-emergency-use-authori
zations-medical-devices/vitro-diagnostics-euas, last accessed
September 9, 2020) using two different reference materials
[FDA Emergency Use Authorization assay by
PerkinElmer Inc. and AccuPlex SARS-CoV-2 Molecular
Controls Kit - Full Genome, Material number 0505-0159
(SeraCare, Milford, MA)]. Briefly, SARS-CoV-2 reference
control materials were spiked into the negative saliva sam-
ples to serve as positive samples at 180, 60, and 20 copies/
mL concentrations, and were processed with SalivaAll
protocol. The lowest concentration detected in all three
triplicates was determined as the preliminary LoD. To
confirm the LoD, 20 replicates of preliminary LoD were
analyzed and deemed as confirmed if at least 19 of 20
replicates were detected. The PerkinElmer Inc. and SeraCare
reference control materials consisted of encapsulated syn-
thetic RNA with concentration of 1000 and 5000 copies/
mL, respectively.
Pooling Saliva Samples for Mass Population Screening
A five-sample pooling strategy was evaluated as per FDA
guidelines. Briefly, 20 previously confirmed positive saliva
samples were identified to generate 20 positive pools, each
comprising of one positive and four negative samples. The
Ct values of positive samples ranged from N of 9.8 and
ORF1ab of 17.3 to N of 38.4 and ORF1ab of undetermined,
Saliva with Pooling Utility for COVID-19
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with 25% of positive samples having high Ct values (32.0 to
38.4). Similarly, 20 negative sample pools were generated,
composed of five negative samples. All saliva samples were
first processed with Omni bead mill homogenizer, as
described in SalivaAll protocol, before pooling for SARS-
CoV-2 real time PCR testing (Figure 1). Of note, each
pool was generated by aliquoting 60 mL from each of the
five homogenized samples to make 300 mL for extraction.
Data Analysis
Data were analyzed for descriptive statistics and presented
as number (percentage) for categorical variables and
means  SD for continuous variables. Ct values were
compared using paired t-test. Regression analysis with slope
and intercept along with a 95% CI was determined in the
pooling sample study.
Results
Comparison of SARS-CoV-2 Detection In Saliva and NPS
[Phase 1 Study: Protocol U(unprocessed)]
Of the 240 matched sample pairs, 28.3% (68/240) tested
positive for SARS-CoV-2 from saliva, NPS, or both. The
detection rate for SARS-CoV-2 was significantly higher in
NPS compared with saliva testing [89.7% (61/68) versus
50.0% (34/68); P < 0.001]. The concordance for positive
results between the two tests was only 39.7% (virus detected
in both saliva and NPS in 27/68). Of the 68 positive sam-
ples, 50% (34/68) were positive in NPS but not in saliva,
whereas only 10.2% (7/68) were positive in saliva but not in
NPS. The Ct values for N (25.2  8.7 versus 29.5  6.4;
P < 0.05), ORF1ab (22.6  7.9 versus 33.5  6.0;
P < 0.001), and IC (32.2  3.5 versus 36.0  4.4;
P < 0.001) were significantly lower in NPS compared with
saliva samples, respectively (Figure 2, A and B). Overall, IC
(extraction and real time PCR control) was detected in 95%
(228/240) NPS samples, and 80.4% (193/240) saliva
samples.
Comparison of SARS-CoV-2 Detection between Saliva
and NPS (Phase 2 Study: SalivaAll)
Of the 189 matched sample pairs tested in phase 2, 50.2%
(95/189) tested positive for SARS-CoV-2 from saliva, NPS,
or both. The detection rate for SARS-CoV-2 was signifi-
cantly higher in saliva compared with that in NPS [97.8%
(93/95) versus 78.9% (75/95); P < 0.001]. The concordance
for positive results between the two tests was 76.8% (virus
detected in both saliva and NPS in 73/95). Of the 95 posi-
tive samples, 21.0% (20/95) were positive in saliva but not
in NPS, whereas only 2.1% (2/95) were positive in NPS but
not in saliva. The Ct values for N (26.9  8.0 versus
26.4  6.9) and ORF1ab (27.0  8.6 versus 29.2  6.3)
were comparable, whereas the IC values (33.4  3.6 versus
31.6  3.4; P < 0.05) were significantly higher in NPS
compared with saliva samples, respectively (Figure 2, C and
D). Overall, IC (extraction and real time PCR control) was
detected in all NPS and saliva samples, except in one saliva
sample. The results were comparable and no difference was
observed in clinical sensitivity in the additional study that
processed 189 NPS samples via protocol U and the bead
mill homogenization (SalivaAll protocol).
Comparison of SARS-CoV-2 Detection in Saliva Samples
(Protocol U versus SalivaAll)
Eighty-five saliva samples, of which 47% (40/85) were
positive, were tested with both protocols. Of these, 57.6%
Figure 3 A: Boxplots of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Ct value of both N and ORF1ab genes of all the positive saliva
specimens detected with protocol U and SalivaAll. Ct value of both genes was lower with SalivaAll compared with protocol U. Also included Ct values of internal
control (IC) of all the samples with both protocols. B: Bar graph depicting the detection rate in the saliva sample with protocol U and SalivaAll. Data are given
as means  SD (A). **P < 0.01, ***P < 0.001. Saliva-U, unprocessed saliva samples.
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(49/85) tested positive for SARS-CoV-2 with protocol U,
SalivaAll, or both. At 100% (49/49), the detection rate was
significantly higher in samples tested with SalivaAll
compared with 36.7% (18/49) tested with protocol U
(P < 0.001). The concordance for positive results between
the two protocols was 36.7% (18/49). The Ct values for N
(25.1  6.0 versus 28.6  5.9) were lower, whereas at
(27.9  6.0 versus 35.2  6.3; P < 0.01) and IC (31.2  2.7
versus 33.7  3.9; P < 0.001), ORF1ab values were
significantly lower with SalivaAll compared with protocol
U, respectively (Figure 3).
Limit of Detection
In the preliminary LoD study, all replicates were detected at
the three tested concentrations with the PerkinElmer Inc.
reference material, and two of three replicated were detected
at 20 copies/mL with SeraCare material. The LoD was
determined to be 20 and 60 copies/mL with PerkinElmer
Inc. and SeraCare material, respectively, and all 20
replicates were detected (Table 1).
Pooling Saliva Samples for Mass Population Screening
The five-sample pooling strategy was evaluated by
comparing the results of the 20 positive and negative pools
with individual sample testing results. The pooled testing
results demonstrated a 95% positive and a 100% negative
agreement. The N and ORF1ab gene Ct values were
compared between pooled and individual testing. The shift
in Ct value was found to be significant, with pooled testing
toward higher Ct values; nonetheless, the pools containing
positive samples with viral loads close to the assay’s LoD
(ie, weak positives) were accurately detected (Table 2 and
Figure 4).
Discussion
An optimal sample type and easier collection method for the
detection of SARS-CoV-2 are primary requirements in the
global effort to control this pandemic. NPS and OPS samples
are the currently recommended sample types for COVID-19
diagnostic testing. Testing for SARS-CoV-2 has relied pri-
marily on these samples, but the associated challenges with
NPS/OPS sampling have engendered a need to evaluate
several other sample types, of which saliva has remained an
attractive alternate. However, there are conflicting reports in
the literature on the clinical performance of saliva compared
with NPS/OPS samples. In a healthcare setting, initial reports
from To et al6,7 demonstrated comparable sensitivity of saliva
samples (86.9% and 91.7%) compared with NPS samples.
Similarly, independent investigations from Azzi et al8 and
Yoon et al9 demonstrated a 100% concordance of saliva with
NPS samples, withYoon et al9 reporting high viral titer values
in saliva. In addition, Wyllie et al10 and Rao et al11 demon-
strated higher sensitivity of saliva and particularly early
morning saliva compared with NPS samples, respectively.
Conversely, Lai et al12 and Jamal et al13 reported lower
sensitivity of deep-throat saliva (68.7% versus 80.9%) and
saliva samples (72% versus 89%) compared with NPS sam-
ples, respectively. Furthermore, Becker et al14 reported a 30%
to 50% lower sensitivity of saliva compared with NPS sam-
ples in the community setting.
The phase 1 study, comprising 240 matched NPS and
saliva sample pairs (protocol U), demonstrated lower
sensitivity of saliva samples compared with NPS samples.
The detection rate in saliva samples was significantly
lower compared with that in NPS samples. In addition,
the Ct values for N, ORF1ab, and IC (extraction and PCR
control) were significantly higher in saliva compared with
that in the NPS samples. Furthermore, a high percentage
of saliva samples yielded invalid results. A significant
challenge in the wet laboratory revolved around accurate
pipetting of saliva samples because most of them were
viscous, even after intensive vortexing. The viscous gel-
like consistency not only caused issues with pipetting
but also led to a high percentage of invalid results. This
was demonstrated as a significantly high Ct value drift in
the IC, suggesting that the lower sensitivity of saliva
samples is most likely the result of processing and
sometimes pre-analytical issue(s). Several factors that
might have led to the lower sensitivity of saliva samples
were contemplated, including inaccurate pipetting of
sample volume into the extraction plate for nucleic acid
Table 1 SARS-CoV-2 Limit of Detection Using SalivaAll Protocol





mean Ct  SD
ORF1ab gene,
mean Ct  SD
20 36.7  0.6 35.1  1.3
60 33.6  0.15 33.7  0.4
180 32.7  0.19 32.6  0.2
Limit of detection confirmation (20 copies/mL): 20/20 replicates
detected.
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 2 Performance of Saliva Pooling with SalivaAll Protocol
Study design: SalivaAll Composition of saliva pools Concordance
Positive pools (20) 1 Positive þ 4 negative (individually tested samples) 19/20
Negative pools (20) 5 Negative (individually tested samples) 20/20
Positive percentage agreement Z 95%. Negative percentage agreement Z 100%.
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extraction, the viscous gel-like texture of saliva samples
preventing appropriate mixing with viral transport media,
and leading to the pipetting of primarily saliva or media
into extraction plate for nucleic acid extraction, and the
likelihood that the higher viscosity of saliva might also
impair sample lysis for nucleic acid extraction.
The underlying issue associated with these challenges
emerged to be the gel-like consistency of saliva samples.
This significant pre-analytic concern was addressed by
adding a simple step before processing samples for nucleic
acid extraction. The saliva samples were homogenized using
a bead mill homogenizer at a speed of 4.5 m/second for 30
seconds (SalivaAll). The homogenization rendered the
saliva samples uniform in viscosity and consistency, making
it easier to pipet for the downstream assay. Thus, in phase 2
of the study, with 189 matched NPS and saliva sample
pairs, adding this single preprocessing step rendered saliva
samples more sensitive compared with NPS samples.
The detection rate was higher in saliva samples, with
significantly lower Ct value for IC, compared with NPS
samples. Of the 85 saliva samples processed both in phase 1
and phase 2 studies, the detection rate was significantly
higher in samples processed with the homogenization step
(SalivaAll) compared with the samples processed without it
(protocol U). The Ct values in the same saliva samples were
lower for the N gene, and significantly lower for ORF1ab
and IC in samples processed with SalivaAll compared with
protocol U. These results demonstrate that the sensitivity of
the saliva samples observed in the phase 1 study was lower
because of inadequate sample processing. The saliva sam-
ples were found to be more sensitive compared with NPS
samples, with the addition of this simple processing step.
Furthermore, the LoD of 20 copies/mL with the Perki-
nElmer Inc. material and 60 copies/mL with the SeraCare
material confirmed the sensitivity of saliva samples as the
LoD was determined to be similar to that for the FDA
Emergency Use Authorization comparator test for NPS
samples. The LoD for the assay in NPS samples was
determined to be 20 copies/mL with PerkinElmer Inc.
positive control and SeraCare reference material. Viscosity
measurement studies were performed to demonstrate the
effect of homogenization on saliva samples. Uunprocessed
saliva samples (Saliva-U) had a viscosity ranging from 176
centipoise (cP) to 677 cP (between the viscosity of olive oil
and honey), compared to that of homogenized samples
(SalivaAll), which had a viscocity of 2.1 cP to 3.1 cP, a
viscosity close to that of water (1 cP). These findings
highlight and explain the difficulty the saliva samples posed
during pipetting and in the extraction procedure, which
made uniform mixing of reagents challenging. The ho-
mogenization of saliva samples led to a uniform and less
viscous sample and allowed adequate extraction of the
nucleic acids in the extraction procedure, leading to higher
sensitivity of the assay.16
Furthermore, saliva processing became significantly
easier, leading to successful validation of saliva samples with
a five-sample pooling strategy. The pooled testing results
demonstrated a positive percentage agreement of 95% (19/20
pools showing positive results), with one pool that contained
the sample with high Ct (N: 38.4; ORF1ab: undetermined)
being undetectable. The negative percentage agreement was
found to be 100%. The feasibility and accuracy of a sample
pooling approach with NPS samples for wide-scale popula-
tion screening for COVID-19 has been demonstrated.17
Herein, the utility and potential benefits of the sample pool-
ing approach were extended for population screening with
saliva samples. Considering the evolving epidemiology of
COVID-19 and the reopening of educational and professional
institutions, travel, tourism, and social activities, monitoring
SARS-CoV-2 is expected to remain a critical public health
need. Therefore, the use of a noninvasive collection method
and easily accessible samples such as saliva, will enhance
screening and surveillance activities.
In conclusion, this study has demonstrated that the saliva
samples are more sensitive than NPS samples if collected
and processed appropriately before extraction and PCR. The
study evaluated matched NPS and saliva sample pairs
collected in both healthcare and community settings. In the
Figure 4 A: The Ct value comparison of N gene with individual testing versus pool testing. B: The Ct value comparison of ORF1ab gene with individual
testing versus pool testing. The equation represents the trendline regression equation and the R2 value.
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community setting, no control was exercised regarding food
or drink restriction and time of sample collection as most of
the community-collected samples came from drive-through
facilities that operate from morning until evening. The
spectrum of disease also varied from asymptomatic to
severely ill patients, and the study was not biased for a
particular group. However, it must be highlighted that ho-
mogenization is an additional step in the workflow and will
increase the processing time compared with NPS samples.
In addition, similar approaches to homogenize the saliva
samples should be evaluated by laboratories intending to
implement saliva testing in different regions of the world,
where this particular homogenizer might not be available.
Furthermore, the study has two limitations: the Ct value in
this study reflects viral load but not the viral copies per mL,
and the sample collection was not controlled for a specific
day of illness. Nonetheless, despite these limitations, this
study presents a significant and clinically validated approach
to the utilization of saliva samples for COVID-19 testing,
individually or as pooled samples.
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